EGFR and lung adenocarcinoma: Herein, we report the impact of EGF+61 A>G genotype over ORR and DCR to first‐generation TKIs (erlotinib and gefitinib) on 111 EGFR‐mutated Brazilian lung adenocarcinoma patients.